Non-invasive index for predicting significant liver fibrosis: Comparison of diagnostic performances in patients with chronic hepatitis B and C

Jae Youn Cheong, Soon-Ho Um, Yeon Seok Seo, Dong Joon Kim, Seong Gyu Hwang, Youn Jae Lee, Mong Cho, Jin Mo Yang, Young Bae Kim, Young Nyun Park, Sung Won Cho

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Background/Aims: The majority of non-invasive markers of liver fibrosis have been developed in patients with chronic hepatitis C. We aimed to develop a formula for predicting significant fibrosis in patients with chronic viral hepatitis and to compare the usefulness of published models derived from the data obtained from patients with chronic hepatitis C. Methods: Serum markers and the METAVIR stage of fibrosis in liver biopsy specimens were compared prospectively in patients with chronic hepatitis B and C (estimation set, 367; validation set, 159). Results: In the estimation set, multiple forward stepwise logistic regression analysis identified γ-glutamyl transpeptidase, haptoglobin, α2-macroglobulin, matrix metalloproteinase-2, and tissue inhibitor of metalloproteinase-1 as independent predictors of significant fibrosis. A formula termed the SF index was constructed with the aforementioned five variables. The areas under the receiver operating characteristic curves of the SF index for predicting significant fibrosis were 0.828, 0.776, and 0.827 in the estimation, validation, and total sets, respectively. Using cut-off scores of 2.2 and 3.3, significant fibrosis was predicted with considerable accuracy. The diagnostic performances of the SF index and the Zeng index derived from chronic hepatitis B patients were much better than indices derived from chronic hepatitis C patients, such as the APRI, Forns index, and FIB-4. Conclusions: We developed a novel formula for predicting significant fibrosis in patients with chronic viral hepatitis. Serum indices from studies in patients with chronic hepatitis C were less accurate in patients with chronic hepatitis B for predicting significant fibrosis.

Original languageEnglish
Pages (from-to)555-563
Number of pages9
JournalDigestive Diseases and Sciences
Volume56
Issue number2
DOIs
Publication statusPublished - 2011 Feb 1

Fingerprint

Chronic Hepatitis B
Chronic Hepatitis C
Liver Cirrhosis
Fibrosis
Chronic Hepatitis
Macroglobulins
Tissue Inhibitor of Metalloproteinase-1
Haptoglobins
Matrix Metalloproteinase Inhibitors
gamma-Glutamyltransferase
Matrix Metalloproteinase 2
ROC Curve
Biomarkers
Logistic Models
Regression Analysis
Biopsy
Serum

Keywords

  • Chronic hepatitis
  • Fibrosis marker
  • Liver fibrosis

ASJC Scopus subject areas

  • Physiology
  • Gastroenterology

Cite this

Non-invasive index for predicting significant liver fibrosis : Comparison of diagnostic performances in patients with chronic hepatitis B and C. / Cheong, Jae Youn; Um, Soon-Ho; Seo, Yeon Seok; Kim, Dong Joon; Hwang, Seong Gyu; Lee, Youn Jae; Cho, Mong; Yang, Jin Mo; Kim, Young Bae; Park, Young Nyun; Cho, Sung Won.

In: Digestive Diseases and Sciences, Vol. 56, No. 2, 01.02.2011, p. 555-563.

Research output: Contribution to journalArticle

Cheong, Jae Youn ; Um, Soon-Ho ; Seo, Yeon Seok ; Kim, Dong Joon ; Hwang, Seong Gyu ; Lee, Youn Jae ; Cho, Mong ; Yang, Jin Mo ; Kim, Young Bae ; Park, Young Nyun ; Cho, Sung Won. / Non-invasive index for predicting significant liver fibrosis : Comparison of diagnostic performances in patients with chronic hepatitis B and C. In: Digestive Diseases and Sciences. 2011 ; Vol. 56, No. 2. pp. 555-563.
@article{152e7f580d5040dca0a324cf8d7930ca,
title = "Non-invasive index for predicting significant liver fibrosis: Comparison of diagnostic performances in patients with chronic hepatitis B and C",
abstract = "Background/Aims: The majority of non-invasive markers of liver fibrosis have been developed in patients with chronic hepatitis C. We aimed to develop a formula for predicting significant fibrosis in patients with chronic viral hepatitis and to compare the usefulness of published models derived from the data obtained from patients with chronic hepatitis C. Methods: Serum markers and the METAVIR stage of fibrosis in liver biopsy specimens were compared prospectively in patients with chronic hepatitis B and C (estimation set, 367; validation set, 159). Results: In the estimation set, multiple forward stepwise logistic regression analysis identified γ-glutamyl transpeptidase, haptoglobin, α2-macroglobulin, matrix metalloproteinase-2, and tissue inhibitor of metalloproteinase-1 as independent predictors of significant fibrosis. A formula termed the SF index was constructed with the aforementioned five variables. The areas under the receiver operating characteristic curves of the SF index for predicting significant fibrosis were 0.828, 0.776, and 0.827 in the estimation, validation, and total sets, respectively. Using cut-off scores of 2.2 and 3.3, significant fibrosis was predicted with considerable accuracy. The diagnostic performances of the SF index and the Zeng index derived from chronic hepatitis B patients were much better than indices derived from chronic hepatitis C patients, such as the APRI, Forns index, and FIB-4. Conclusions: We developed a novel formula for predicting significant fibrosis in patients with chronic viral hepatitis. Serum indices from studies in patients with chronic hepatitis C were less accurate in patients with chronic hepatitis B for predicting significant fibrosis.",
keywords = "Chronic hepatitis, Fibrosis marker, Liver fibrosis",
author = "Cheong, {Jae Youn} and Soon-Ho Um and Seo, {Yeon Seok} and Kim, {Dong Joon} and Hwang, {Seong Gyu} and Lee, {Youn Jae} and Mong Cho and Yang, {Jin Mo} and Kim, {Young Bae} and Park, {Young Nyun} and Cho, {Sung Won}",
year = "2011",
month = "2",
day = "1",
doi = "10.1007/s10620-010-1305-3",
language = "English",
volume = "56",
pages = "555--563",
journal = "American Journal of Digestive Diseases",
issn = "0002-9211",
publisher = "Springer New York",
number = "2",

}

TY - JOUR

T1 - Non-invasive index for predicting significant liver fibrosis

T2 - Comparison of diagnostic performances in patients with chronic hepatitis B and C

AU - Cheong, Jae Youn

AU - Um, Soon-Ho

AU - Seo, Yeon Seok

AU - Kim, Dong Joon

AU - Hwang, Seong Gyu

AU - Lee, Youn Jae

AU - Cho, Mong

AU - Yang, Jin Mo

AU - Kim, Young Bae

AU - Park, Young Nyun

AU - Cho, Sung Won

PY - 2011/2/1

Y1 - 2011/2/1

N2 - Background/Aims: The majority of non-invasive markers of liver fibrosis have been developed in patients with chronic hepatitis C. We aimed to develop a formula for predicting significant fibrosis in patients with chronic viral hepatitis and to compare the usefulness of published models derived from the data obtained from patients with chronic hepatitis C. Methods: Serum markers and the METAVIR stage of fibrosis in liver biopsy specimens were compared prospectively in patients with chronic hepatitis B and C (estimation set, 367; validation set, 159). Results: In the estimation set, multiple forward stepwise logistic regression analysis identified γ-glutamyl transpeptidase, haptoglobin, α2-macroglobulin, matrix metalloproteinase-2, and tissue inhibitor of metalloproteinase-1 as independent predictors of significant fibrosis. A formula termed the SF index was constructed with the aforementioned five variables. The areas under the receiver operating characteristic curves of the SF index for predicting significant fibrosis were 0.828, 0.776, and 0.827 in the estimation, validation, and total sets, respectively. Using cut-off scores of 2.2 and 3.3, significant fibrosis was predicted with considerable accuracy. The diagnostic performances of the SF index and the Zeng index derived from chronic hepatitis B patients were much better than indices derived from chronic hepatitis C patients, such as the APRI, Forns index, and FIB-4. Conclusions: We developed a novel formula for predicting significant fibrosis in patients with chronic viral hepatitis. Serum indices from studies in patients with chronic hepatitis C were less accurate in patients with chronic hepatitis B for predicting significant fibrosis.

AB - Background/Aims: The majority of non-invasive markers of liver fibrosis have been developed in patients with chronic hepatitis C. We aimed to develop a formula for predicting significant fibrosis in patients with chronic viral hepatitis and to compare the usefulness of published models derived from the data obtained from patients with chronic hepatitis C. Methods: Serum markers and the METAVIR stage of fibrosis in liver biopsy specimens were compared prospectively in patients with chronic hepatitis B and C (estimation set, 367; validation set, 159). Results: In the estimation set, multiple forward stepwise logistic regression analysis identified γ-glutamyl transpeptidase, haptoglobin, α2-macroglobulin, matrix metalloproteinase-2, and tissue inhibitor of metalloproteinase-1 as independent predictors of significant fibrosis. A formula termed the SF index was constructed with the aforementioned five variables. The areas under the receiver operating characteristic curves of the SF index for predicting significant fibrosis were 0.828, 0.776, and 0.827 in the estimation, validation, and total sets, respectively. Using cut-off scores of 2.2 and 3.3, significant fibrosis was predicted with considerable accuracy. The diagnostic performances of the SF index and the Zeng index derived from chronic hepatitis B patients were much better than indices derived from chronic hepatitis C patients, such as the APRI, Forns index, and FIB-4. Conclusions: We developed a novel formula for predicting significant fibrosis in patients with chronic viral hepatitis. Serum indices from studies in patients with chronic hepatitis C were less accurate in patients with chronic hepatitis B for predicting significant fibrosis.

KW - Chronic hepatitis

KW - Fibrosis marker

KW - Liver fibrosis

UR - http://www.scopus.com/inward/record.url?scp=79952448633&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952448633&partnerID=8YFLogxK

U2 - 10.1007/s10620-010-1305-3

DO - 10.1007/s10620-010-1305-3

M3 - Article

C2 - 20585981

AN - SCOPUS:79952448633

VL - 56

SP - 555

EP - 563

JO - American Journal of Digestive Diseases

JF - American Journal of Digestive Diseases

SN - 0002-9211

IS - 2

ER -